Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926367 · ClinicalTrials.gov registry record · Phase 4
Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications
A Phase 4 study, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT00926367 is a Phase 4 study that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 52 participants.
The verdict
NCT00926367, a Phase 4 study, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a single-blind (blinded expert grader), randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, antibiotic and benzoyl peroxide or benzoyl peroxide and adapalene gel and the contra lateral side of the face will remain non-treated to serve as a control. Approximately 25-30 male and female healthy subjects will be randomly assigned to each product
Interventions
- DRUG Clindamycin and benzoyl peroxide
- DRUG benzoyl peroxide 2.5% and adapalene 0.1% gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2009-05 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00926367
The ClinicalTrials.gov registry entry for NCT00926367 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clindamycin and benzoyl peroxide is the first listed.
NCT00926367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00926367 about?
NCT00926367 is a clinical study titled "Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications". This is a single-blind (blinded expert grader), randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, antibiotic and benzoyl peroxide or benzoyl peroxide and adapalene gel and the contra lateral side of the face will...
What is the current status of trial NCT00926367?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2009-05. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00926367?
The interventions under investigation include: Clindamycin and benzoyl peroxide (DRUG), benzoyl peroxide 2.5% and adapalene 0.1% gel (DRUG).
Who is sponsoring clinical trial NCT00926367?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.